Abstract. We report a rare case of type 1 diabetes in a woman associated with acromegaly who was treated with surgery after pregnancy. An 18-year-old woman came to our hospital in April, 1998, complaining of thirst, polydipsia, polyuria, appetite loss, body weight loss of 8 kg in a month, and amenorrhea beginning 2 months earlier. Based on laboratory data, she was diagnosed as having type 1 diabetes mellitus. Although we suspected her of having acromegaly because of high growth hormone (GH) levels (6.9 or 8.5 ng/ml), blood levels of insulin-like growth factor 1 (IGF-1) and IGF-binding protein-3 (IGFBP-3) were within normal range and the circadian rhythm of her blood GH levels was normally maintained. Her blood GH level was elevated to 12.6 ng/ml 15 minutes after a TRH administration. Blood GH levels were suppressed from 49 ng/ml to 1.5 ng/ml 4 hours after an oral administration of 2.5 mg of bromocriptine. A magnetic resonance images (MRIs) showed pituitary swelling, but no nodules were found in the pituitary. Therefore, we diagnosed her as having acromegaly and observed her without surgery, while prescribing diet therapy and intensive insulin therapy for diabetes. We started a treatment of oral administration of 7.5 mg of bromocriptine per day for the acromegaly from April 28, 2000, because her elevated GH was suspected of causing her diabetes to be poorly controlled. During a pregnancy from October, 2000 to September, 2001, diabetic control was improved with increased administration of insulin under a constant dose of bromocriptine. She delivered a normal full-term infant. After the bromocriptine therapy was stopped as she hoped to breastfeed, blood levels of GH and IGF-1 became elevated and her diabetic control deteriorated. As her pituitary tumor observed in pituitary MRIs became larger during the course, a transsphenoidal surgery was performed on March 8, 2002. After the surgery, blood levels of GH and IGF-1 lowered and diabetic control improved again. We concluded as follows: to rule out acromegaly in patients with poorly controlled diabetes, 1) measurements of serum GH and IGF-1 should be performed, and 2) pituitary MRIs should be performed if blood levels of GH or IGF-1 are high.
ACROMEGALY is a disease induced by a growth hormone (GH)-producing tumor. The excessive production of GH and insulin-like growth factor 1 (IGF-1) causes various diseases such as diabetes mellitus, hypertension, and hyperlipidemia, of which the frequency of diabetes is 5-32% [1, 2] . Diabetes in acromegaly is due to a mechanism in which excessive GH production induces both hyperinsulinemia and insulin resistance, leading to elevated blood glucose levels [2] [3] [4] . In type 1 diabetes, particularly if it is poorly controlled, blood GH levels are generally higher and fluctuate more than in non-diabetics because their deficient endogeneous insulin tends to increase GH secretion [4] [5] [6] .
The diagnostic evaluation of acromegaly is usually undertaken by noting typical clinical symptoms, high blood levels of GH and IGF-1, and the existence of a pituitary tumor seen in magnetic resonance images (MRIs) [1] . The measurement of serum IGF-1 and IGF-binding protein-3 (IGFBP-3) has been reported as being valuable for the diagnosis of acromegaly in type 1 diabetes [7, 8] . However, it may be sometimes difficult to diagnose acromegaly associated with type 1 diabetes because insulin, GH and IGF-1 may mutually interfere with each other on secretion [9] .
We report a rare case of type 1 diabetes with acromegaly, which was diagnosed by endocrinological stimulation tests and pituitary MRIs and successfully treated with surgery after pregnancy.
Clinical Course
An 18-year-old woman came to our hospital on April 9, 1998, complaining of thirst, polydipsia, polyuria, appetite loss, body weight loss of 8 kg in a month, and amenorrhea beginning 2 months earlier, but not of headache. Based on laboratory data showing a high blood glucose level (547 mg/dl) and positive urinary acetone body (Table 1) , she was diagnosed as suffering from diabetic ketosis. As her blood GH level was 3.5 ng/ml, which was above the normal range of below 3.0 ng/ml (enzyme immunoassay, EIA), acromegaly was also suspected. She was admitted to our hospital in April, 1998, to undergo examinations and treatment for diabetes associated with elevated blood GH.
Her physical examinations on admission were as follows: height 162.1 cm, body weight 50.6 kg, body mass index (BMI) 19.3, blood pressure 118/76 mmHg. Thyroid was not palpable and no nodule was palpated in her thyroid. She had neither visual disturbances nor diplopia. She had no abnormalities in the heart, lungs or abdomen. She had no typical symptoms of acromegaly, such as enlarged hands and feet, exaggerated nasolabial folds, thick lips, giant tongue, etc. Tendon reflex was normal. Heel pad of 16 mm was within normal range. Radiograph of the finger showed normal. Her fingers were not thickened and did not have spadelike distal tufts.
We diagnosed her as having type 1 diabetes mellitus based on data showing low levels of urinary C-peptide (CPR) excretion (10.4 mg/day) ( Table 1 ) and a high titer of anti-glutamic acid decarboxylase (GAD) antibodies (29.1 U/ml) ( Table 2 ). There was hyperglycemia, but there were no abnormal findings in blood cell count, renal function, liver function, or blood amylase levels ( Table 1) . She did not have diabetic neuropathy, retinopathy or nephropathy. Although blood levels of CEA (6.1 ng/ml) and CA19-9 (110 U/ml) were elevated (Table 1) , no malignancies were seen on images such as abdominal computed tomography (CT) scan, gastro-intestinal fiberscopy, or barium enema.
Although her blood GH levels (6.9 or 8.5 ng/ml) and urinary GH/Cr excretion (24.1 pg/mgCr) were both high, blood levels of IGF-1 (316 ng/ml, immunoradiometric assay, IRMA) and IGFBP-3 (2.64 mg/ml, radioimmunoassay, RIA) were within the normal range (Tables 2, 3 ). The responses of GH, PRL, and TSH to TRH were discrepancy hyperactive (as blood GH level increased to 12.6 ng/ml), hyperactive, and hypoactive, respectively (Fig. 1A ). Blood levels of GH at 4 hours and PRL at 6-8 hours after an oral administration of 2.5 mg of bromocriptine were suppressed from 4.9 ng/ ml to 1.5 ng/ml and from 20.2 ng/ml to <1.0 ng/ml, respectively (Fig. 1B) . Although her fasting blood GH level in the morning was slightly high, the circadian rhythm of her blood GH levels was normally maintained (Fig. 1C) Fig. 2A, B) . Thus, based on endocrinological data, we diagnosed her as having acromegaly. Blood levels of cortisol, ACTH, free T4, TSH, PRL, LH, and FSH were normal. Both the anti-GAD antibodies and anti-nuclear bodies were positive, and, conversely, the antibodies against insulin, the pituitary and the thyroid were all negative ( Table 2 ). Blood levels of calcium, phosphorus, intact-PTH, 1a-25(OH) 2 VD, cathecholamine, glucagon, gastrin, and calcitonin were all normal (Table 1 , 2). She did not have any tumors on neck-and abdomen ultrasonography or abdominal CT scans. Thus, we excluded multiple endocrine neoplasia type 1 (MEN1) and diagnosed her condition as plain acromegaly. We prescribed diet therapy (1400 Kcal/ day) and an intensive insulin therapy of rapid-acting insulin (Penfill R R ) at each meal and intermediate-acting NPH insulin (Penfill N R ) at bedtime for her diabetes.
Diabetic control just after leaving the hospital on June 12, 1998 was good (HbA1c 6.1%). Subsequently, we increased the insulin dose from 22 units to 40 units per day because her blood glucose levels fluctuated between hypo-and hyperglycemia. We started the treatment of oral administration of 7.5 mg of bromocriptine per day for the acromegaly beginning April 28, 2000, because high blood levels of GH were suspected of causing her diabetes to be poorly controlled. However, she rejected octoreotide therapy because octoreotide was expensive. During her pregnancy from October, 2000 to September, 2001, diabetic control improved by the oral administration of bromocriptine and increased insulin injection (Fig. 3) . While she was receiving the treatments of the oral administration of bromocriptine for acromegaly and the insulin injections for type 1 diabetes, she became pregnant and delivered a normal male infant at 41 weeks (weight: 3936 g). The baby transiently had hypoglycemia (blood glucose levels Abbreviations: GAD, glutamic acid decarboxylase; ANA, antinuclear antibody; TGPA, anti-thyroglobulin particle agglutination; MCPA, anti-thyroid microsomal particle agglutination. * Numbers in parentheses indicate the normal range. Responses of GH, PRL and TSH to TRH were discrepantly hyperactive (as blood GH level increased to 12.6 ng/ml), hyperactive and hypoactive, respectively. (B) Bromocriptine suppression test. Blood levels of GH at 4 hours and PRL at 6-8 hours after an oral administration of 2.5 mg of bromocriptine were suppressed. (C) Circadian rhythm of blood GH levels. Although her fasting blood GH level in the morning was slightly high, the circadian rhythm of blood GH levels was normally maintained. 50-60 mg/dl) and jaundice (total bilirubin 14.9 mg/dl), but showed no deformities. After delivery, the oral administration of bromocriptine was stopped because she hoped to breastfeed. Thereafter, blood levels of GH and IGF-1 became elevated and her diabetic control deteriorated (Fig. 3) . In February, 2002, although blood IGFBP-3 level was within the normal range, her blood levels of GH (2.2 ng/ml) and IGF-1 (462 ng/ml) and urinary GH/Cr excretion (26.6 pg/mgCr) were high (Table 3 ). An enhanced MRI on February 2, 2002, showed one low intensity lesion of about 8 mm diameters in the anterior lobe of the pituitary (Fig. 4A, B) . As the pituitary tumor gradually became larger, she underwent a transsphenoidal surgery for one pituitary tumor on March 8, 2002 . From the pathological point of view, the pituitary tumor was composed of acidophilic cells (Fig. 5) . Immunohistochemical staining of GH and PRL was done using a ×100 dilution of anti-GH serum (Novocastra, Newcastle, UK) and a ×100 dilution of anti-PRL serum (Novocastra, Newcastle, UK), respectively. The tumor cells showed strong and diffuse cytoplasmic immunoreactivity for GH, but not for PRL (data not shown). This pituitary tumor was diagnosed as a GH-producing and closely granulated somatotroph adenoma. After the surgical resection of the pituitary tumor, blood levels of GH, IGF-1 and IGFBP-3 lowered and diabetic control improved (Table 3) . A woman was diagnosed as having type 1 diabetes mellitus and acromegaly in 1998. As MRIs showed no nodule in the pituitary, we observed her as having acromegaly without necessitating surgery, and prescribed a medical treatment of insulin therapy for the diabetes. We started a treatment of oral administration of bromocriptine for the acromegaly beginning April 28, 2000, because high blood levels of GH were suspected of causing the diabetes to be poorly controlled. While taking the treatments of bromocriptine for acromegaly and insulin for diabetes during a pregnancy from October, 2000 to September, 2001, she delivered a normal infant. After delivery, her pituitary tumor became enlarged, and a transsphenoidal surgery for the tumor was performed on March 8, 2002 . After the surgery, blood levels of GH and IGF-1 lowered and diabetic control improved.
Discussion
We report here a woman who was diagnosed as having acromegaly when suffering from a sudden onset of type 1 diabetes. As insulin induces the expression of GH receptors on hepatocytes, which are the major sites of IGF-1 production, poorly controlled diabetes with a lack of insulin action leads to a state of hepatic GH resistance. Consequently, b-cell dysfunction causes blood GH levels to elevate and blood IGF-1 levels to lower or normalize [9] . Thus, high blood GH levels do not always mean acromegaly. The diagnostic evaluation of acromegaly is undertaken by noting clinical symptoms, high blood levels of GH and IGF-1, and the existence of a pituitary tumor seen in MRIs [2] . The measurements of serum IGF-1 or IGFBP-3 have been reported as being more valuable for diagnosing acromegaly in type 1 diabetes than a single measurement of GH [7, 8] . In the present case, although blood IGFBP-3 levels were always within the normal range, blood levels of GH and IGF-1 were frequently high and a mass was observed on pituitary MRI. Based on the above findings we diagnosed our patient as having acromegaly. Thus, we considered that the measurements of serum GH and IGF-1 and the pituitary MRIs may be valuable for the diagnosis of acromegaly in type 1 diabetes.
The treatments of acromegaly should adequately be selected among medical therapy, radiation, or surgery [11] . As MRIs on first admission showed no mass in her pituitary, we initially chose medication. Although bromocriptine used for acromegaly lowered blood GH levels, her pituitary tumor enlarged after pregnancy. This suggests that pregnancy may aggravate pituitary tumor growth [12] , and in a small number of cases, acromegaly was reported to be exacerbated during pregnancy [12] [13] [14] [15] . As her pituitary tumor clearly became larger in the course of observation, we conducted transsphenoidal surgery on March 8, 2002 . We pathologically diagnosed the specimen as a GH-producing pituitary adenoma because it was immunohistochemically stained with an anti-GH serum. Her clinical features, such as sudden onset of diabetes, high titers of anti-GAD antibodies, and low levels of urinary CPR excretion, were compatible with type 1 diabetes. In addition, the patient was shown to possess an HLA allele susceptible to type 1 diabetes, as DR3, DR4, HLA-DNA typing DQB1*0301, and DQB1*0201 [10] . Therefore, we diagnosed her as having type 1 diabetes and started her on an intensive insulin therapy for the condition. Late pregnancies have been known to contribute to insulin resistance [20] , of which there are various factors causing this, such as free fatty acid (FFA) and tumor necrosis factor-a (TNF-a) [16] [17] [18] [19] . Acromegalic patients during pregnancy are therefore at a greater risk for hyperglycemia [2, 3, 20] . Diabetic control during pregnancy in the present case was improved by the combined treatment of bromocriptine for acromegaly and insulin for diabetes.
In several reports, bromocriptine has been reported to be useful throughout pregnancy without any teratogenic effects because it does not affect the expected pattern of placental hormone secretion [21, 22] . In the present case, while the patient received the treatments of bromocriptine for acromegaly and insulin for type 1 diabetes during her pregnancy, she was eventually able to have a successful pregnancy and deliver a normal full-term infant.
Thus, we reported a rare case of type 1 diabetes mellitus associated with acromegaly, who was diagnosed by both endocrinological stimulation tests and pituitary MRIs after being observed for about 4 years. We concluded that to rule out acromegaly in patients with poorly controlled diabetes, 1) measurements of serum GH and IGF-1 should be performed, and 2) pituitary MRIs should be performed if blood levels of GH or IGF-1 are high.
